Table I.
Patient characteristics and observations during and after surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
| Variables | Patients | ||||
|---|---|---|---|---|---|
|
| |||||
| 1 | 2 | 3 | 4 | 5 | |
| Age (years) | 69 | 60 | 73 | 60 | 47 |
| Gender | Male | Male | Female | Male | Female |
| Performance statusa | 0 | 1 | 0 | 0 | 0 |
| Clinical stageb | Peritoneal recurrence (12 months after 1st surgery) | Peritoneal recurrence (19 months after 1st surgery) | T4aN1aM0 Stage IIIB |
T4aN0M0 Stage IIB |
T3N2bM1b Stage IVB |
| Histology (adenocarcinoma) | Moderately differentiated | Moderately differentiated | Moderately differentiated | Well-differentiated | Moderately differentiated |
| Invasion of other organs | Rectum | Duodenum, right kidney, small intestine | Uterus, bladder | None | None |
| PM | Present | Present | Suspected | Absent | Present |
| Peritoneal cancer index | 2 | 2 | 0 | 0 | 1 |
| Intraoperative cytology | Positive | Negative | Negative | Positive | Positive |
| Complications | Ileus (grade 3), parotitis | Superficial surgical site infection (grade 3) | None | None | None |
| Toxicity | Increased alanine aminotransferase (grade 1) | Increased total bilirubin and creatinine, decreased hemoglobin (grade 1) | Decreased hemoglobin (grade 1) | None | None |
| Hospital stay (days) | 22 | 11 | 15 | 17 | 9 |
| Observation (months) | 44 | 40 | 38 | 35 | 16 |
| Recurrence after HIPEC | Lung, liver (13 months) | Lung (7 months) | None | Liver (14 months) | Liver (3 months) Ovary (12 months) |
| Treatment after HIPEC | Chemotherapy | Chemotherapy | None | Hepatectomy | Chemotherapy; surgery for ovarian metastasis |
| Second observation after HIPEC | None | None | None | No evidence of PM; cytology (−) | No evidence of PM; cytology (−) |
a
ECOG, Eastern Cooperative Oncology Group. PM, peritoneal metastases.
b
Classified according to the UICC TNM classification, version 7.